Search Results - "Chiba, P."

Refine Results
  1. 1

    Classification of arm swing as a clinical marker of advancing spinal deformity among community-dwelling female volunteers 60 years or older by Kobayashi, Tetsuya, Jimbo, Shizuo, Senoo, Issei, Shimizu, Mutsuya, Ito, Hiroshi, Hisashi Chiba, P. T.

    Published in Scientific reports (20-05-2019)
    “…The clinical characteristics of adult spinal deformity (ASD) include worsening of deformity during gait, which leads to unstable posture and propensity to…”
    Get full text
    Journal Article
  2. 2

    First results of a national external quality assessment scheme for the detection of SARS-CoV-2 genome sequences by Görzer, I., Buchta, Ch, Chiba, P., Benka, B., Camp, J.V., Holzmann, H., Puchhammer-Stöckl, E., Aberle, S.W.

    Published in Journal of clinical virology (01-08-2020)
    “…•Implementation of SARS-CoV-2 genome testing by numerous laboratories in Austria.•Broad range of combinations of nucleic acid extraction and RT-PCR…”
    Get full text
    Journal Article
  3. 3

    Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters by Klepsch, F, Jabeen, I, Chiba, P, Ecker, G F

    Published in Current pharmaceutical design (01-05-2010)
    “…ABC-transporter have been recognized as being responsible for multiple drug resistance in tumor therapy, for decreased brain uptake and low oral…”
    Get more information
    Journal Article
  4. 4
  5. 5

    Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24) by Heffeter, P., Jakupec, M.A., Körner, W., Chiba, P., Pirker, C., Dornetshuber, R., Elbling, L., Sutterlüty, H., Micksche, M., Keppler, B.K., Berger, W.

    Published in Biochemical pharmacology (15-06-2007)
    “…Recently, we have introduced [tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772, FFC24) as a new lanthanum compound which has promising anticancer…”
    Get full text
    Journal Article
  6. 6

    Future directions for drug transporter modelling by Ekins, S., Ecker, G. F., Chiba, P., Swaan, P. W.

    Published in Xenobiotica (01-10-2007)
    “…Since the late 1980s computational methods such as quantitative structure-activity relationship (QSAR) and pharmacophore approaches have become more widely…”
    Get full text
    Journal Article
  7. 7
  8. 8

    The importance of a nitrogen atom in modulators of multidrug resistance by Ecker, G, Huber, M, Schmid, D, Chiba, P

    Published in Molecular pharmacology (01-10-1999)
    “…The presence of a nitrogen atom, charged at physiological pH, has frequently been considered to be a hallmark of P-glycoprotein (PGP) inhibitors, although…”
    Get more information
    Journal Article
  9. 9

    Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance by Chiba, P, Ecker, G, Schmid, D, Drach, J, Tell, B, Goldenberg, S, Gekeler, V

    Published in Molecular pharmacology (01-06-1996)
    “…The sodium channel blocker propafenone and a series of analogs have been identified as effective modulators of P-glyco-protein-mediated multidrug resistance in…”
    Get more information
    Journal Article
  10. 10

    Structure–activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements by Schmid, Diethart, Ecker, Gerhard, Kopp, Stephan, Hitzler, Manuela, Chiba, Peter

    Published in Biochemical pharmacology (01-11-1999)
    “…Propafenone analogs (PAs) were previously identified as potent inhibitors of P-glycoprotein (Pgp)-mediated toxin efflux. For this as well as other classes of…”
    Get full text
    Journal Article
  11. 11

    Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance by Kaiser, D, Smiesko, M, Kopp, S, Chiba, P, Ecker, G F

    “…Overexpression of membrane bound, ATP-dependent transport proteins is one of the predominant mechanisms leading to multiple drug resistance in tumor therapy as…”
    Get more information
    Journal Article
  12. 12

    Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview by Ecker, G, Chiba, P

    Published in Wiener Klinische Wochenschrift (1995)
    “…Resistance of tumor cells to a wide variety of cytotoxic agents represents a major problem in cancer therapy. In most cases, the cross resistance profile has…”
    Get more information
    Journal Article
  13. 13

    Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells by Yuan, Yueling, Cai, Tiange, Callaghan, Richard, Li, Qianwen, Huang, Yinghong, Wang, Bingyue, Huang, Qingqing, Du, Manling, Ma, Qianqian, Chiba, Peter, Cai, Yu

    Published in International journal of nanomedicine (01-01-2019)
    “…Psoralen (PSO), a major active component of Psoralea corylifolia, has been shown to overcome multidrug resistance in cancer. A drug carrier comprising a…”
    Get full text
    Journal Article
  14. 14

    Flagging Drugs That Inhibit the Bile Salt Export Pump by Montanari, Floriane, Pinto, Marta, Khunweeraphong, Narakorn, Wlcek, Katrin, Sohail, M. Imran, Noeske, Tobias, Boyer, Scott, Chiba, Peter, Stieger, Bruno, Kuchler, Karl, Ecker, Gerhard F

    Published in Molecular pharmaceutics (04-01-2016)
    “…The bile salt export pump (BSEP) is an ABC-transporter expressed at the canalicular membrane of hepatocytes. Its physiological role is to expel bile salts into…”
    Get full text
    Journal Article
  15. 15

    Computational models for prediction of interactions with ABC-transporters by Ecker, Gerhard F., Stockner, Thomas, Chiba, Peter

    Published in Drug discovery today (01-04-2008)
    “…The polyspecific ligand recognition pattern of ATB-binding cassette (ABC)-transporters, combined with the limited knowledge on the molecular basis of their…”
    Get full text
    Journal Article
  16. 16

    Artificial neural networks as versatile tools for prediction of MDR-modulatory activity by Tmej, C, Chiba, P, Schaper, K J, Ecker, G, Fleischhacker, W

    “…Following our ongoing studies on structure-activity relationship studies of propafenone-type modulators of multidrug resistance, we performed both a…”
    Get more information
    Journal Article
  17. 17

    P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach by Pleban, Karin, Kopp, Stephan, Csaszar, Edina, Peer, Michael, Hrebicek, Thomas, Rizzi, Andreas, Ecker, Gerhard F, Chiba, Peter

    Published in Molecular pharmacology (01-02-2005)
    “…P-glycoprotein (P-gp) is an energy-dependent multidrug efflux pump conferring resistance to cancer chemotherapy. Characterization of the mechanism of drug…”
    Get more information
    Journal Article
  18. 18

    Investigation of cytotoxic effects of 8 norbornane derivatives on 4 human cancer cell lines using the MTT assay by Jäger, W, Päsler, B, Buchbauer, G, Chiba, P

    Published in Pharmazie (01-09-1995)
    “…A group of 8 structurally modified norbornane analogs, selected on basis of water solubility, was tested for its potential cytotoxic effects using a modified…”
    Get more information
    Journal Article
  19. 19

    Self-Organizing Maps for Identification of New Inhibitors of P-Glycoprotein by Kaiser, Dominik, Terfloth, Lothar, Kopp, Stephan, Schulz, Jan, de Laet, Randolf, Chiba, Peter, Ecker, Gerhard F, Gasteiger, Johann

    Published in Journal of medicinal chemistry (05-04-2007)
    “…Self-organizing maps were trained to separate high- and low-active propafenone-type inhibitors of P-glycoprotein. The trained maps were subsequently used to…”
    Get full text
    Journal Article
  20. 20

    P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir by JANNEH, Omar, ANWAR, Tariq, JUNGBAUER, Christof, KOPP, Stefan, KHOO, Saye H, BACK, David J, CHIBA, Peter

    Published in Antiviral therapy (01-01-2009)
    “…Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for…”
    Get full text
    Journal Article